本則回應

• Lopi標記此篇為：💬 含有個人意見

  理由

  1⃣️原文引用的報導可見於中央通訊社《Taiwan's CDC to publish Medigen COVID-19 research in U.S. journal》，參考[1][2].
  2⃣️報導中提到的是台灣疾管署CDC 投稿美國CDC的 “Emerging Infecti
  閱讀更多

  不同意見

  [1]中央社 Taiwan's CDC to publish Medigen COVID-19 research in U.S. journal
  https://focustaiwan.tw/sci-tech/202402020014
  [2] https://tw.news.yahoo.com/高端疫苗效力-相近-bnt-⋯52584.html#:~:text=研究結果顯示，接種3,住院具相似保護效益。 VACCINE EFFICACY 2024.1
  [3] Population-Based Evaluation of Vaccine Effectiveness against SARS-CoV-2 Infection, Severe Illness, and Death, Taiwan
  https://wwwnc.cdc.gov/eid/article/30/3/23-0893_article

  Taiwan's CDC to publish Medigen COVID-19 research in U.S. journal - Focus Taiwan

  https://focustaiwan.tw/sci-tech/202402020014

  Taipei, Feb. 2 (CNA) A COVID-19 vaccine research from Taiwan-based Medigen Vaccine Biologics Corp., which found its locally-produced vaccine was as effective as the Moderna and Pfizer BioNTech vaccine

  高端疫苗效力「相近」BNT！疾管署研究背書 台灣真實世界數據登美CDC期刊

  https://tw.news.yahoo.com/高端疫苗效力-相近-bnt-疾管署研究背書-台灣真實世界數據登美cdc期刊-032052584.html#:~:text=研究結果顯示，接種3,住院具相似保護效益。

  CNEWS匯流新聞網記者陳鈞凱／台北報導 國產的高端新冠疫苗效力一直備受質疑，疾管署今（2）日公布最新獲得美國CDC官方期刊「新興傳染病」接受刊登的國內最新研究結果，依據台灣疫情期間大量接種的真實世界數據顯示，mRNA與蛋白質次單元疫苗，對預防新冠中重症住院具相似保護效益，不管是打BNT還是打高端，保護力都破9成以上。 疾管署是在111年國內首度爆發Omic...

  Population-Based Evaluation of Vaccine Effectiveness against SARS-CoV-2 Infection, Severe Illness, and Death, Taiwan

  https://wwwnc.cdc.gov/eid/article/30/3/23-0893_article

  Vaccine Effectiveness against SARS-CoV-2, Taiwan